Company news

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news

Syndax Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 2, 2026: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news

Press releases & updates

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax Announces Participation in Upcoming Investor Conferences

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Syndax Announces Participation in November Investor Conferences

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Syndax Announces Participation in September Investor Conferences

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

Syndax Announces Participation in June Investor Conferences

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

Syndax Announces Participation in May Investor Conferences

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Syndax Announces Participation in March Investor Conferences

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Syndax Announces Participation in February Investor Conferences